Welcome To The Ambrilia Biopharma HUB On AGORACOM
A biotechnology company dedicated to the discovery and development of novel treatments for viral diseases and cancer
Ambrilia Biopharma Profile
Ambrilia Biopharma
Ambrilia Biopharma Inc. (TSX:AMB) is a biotechnology company dedicated to the discovery and development of novel treatments for viral diseases and cancer. Ambrilia’s product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a therapeutic peptide for prostate cancer, a targeted delivery platform for cancer, HIV protease, integrase and entry inhibitor programs, and a HCV polymerase inhibitor program.
The strategy aims to capitalize on the Company’s broad portfolio and original expertise in virology.
Last changed at 09-Dec-2009 02:03PM by renaissance